{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:43Z","timestamp":1794047443009,"version":"4.8.0"},"reference-count":35,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Despite recent advances in the therapy of diffuse large B-cell lymphoma (DLBCL), many patients are still not cured. Therefore, new therapeutic strategies are needed. The anti-apoptotic B-cell lymphoma 2 (BCL2) gene is commonly dysregulated in DLBCL due to various mechanisms such as chromosomal translocation t(14;18)(q32;q21) and copy number alterations; however, targeting BCL-2 with the selective inhibitor, venetoclax, led to response in only a minority of patients. Thus, we sought to identify a rational combination partner of venetoclax to improve its activity against DLBCL cells. Utilizing a functional assay, dynamic BH3 profiling, we found that the DNA hypomethylating agent decitabine increased mitochondrial apoptotic priming and BCL-2 dependence in DLBCL cells. RNA-sequencing analysis revealed that decitabine suppressed the pro-survival PI3K-AKT pathway and altered the mitochondria membrane composition in DLBCL cell lines. Additionally, it induced a DNA damage response and increased BAX and BAK activities. The combination of decitabine and venetoclax synergistically suppressed proliferation of DLBCL cells both in vitro and in vivo in a DLBCL cell line-derived xenograft mouse model. Our study suggests that decitabine plus venetoclax is a promising combination to explore clinically in DLBCL.<\/jats:p>","DOI":"10.3324\/haematol.2023.283245","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T03:28:43Z","timestamp":1691033323000},"page":"186-199","source":"Crossref","is-referenced-by-count":8,"title":["Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax"],"prefix":"10.3324","volume":"109","author":[{"given":"Fen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyet-Minh","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J. F.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"56296","doi-asserted-by":"crossref","unstructured":"Chapuy B, Stewart C, Dunford AJ. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690.","DOI":"10.1038\/s41591-018-0016-8"},{"key":"56297","doi-asserted-by":"crossref","unstructured":"Schmitz R, Wright GW, Huang DW. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.","DOI":"10.1056\/NEJMoa1801445"},{"key":"56298","doi-asserted-by":"crossref","unstructured":"Wright GW, Huang DW, Phelan JD. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020; 37(4):551-568.","DOI":"10.1016\/j.ccell.2020.03.015"},{"key":"56299","doi-asserted-by":"crossref","unstructured":"Alizadeh AA, Eisen MB, Davis RE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.","DOI":"10.1038\/35000501"},{"key":"56300","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Chan WC. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-1947.","DOI":"10.1056\/NEJMe020050"},{"key":"56301","doi-asserted-by":"crossref","unstructured":"Huang JZ, Sanger WG, Greiner TC. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002; 99(7):2285-2290.","DOI":"10.1182\/blood.V99.7.2285"},{"key":"56302","doi-asserted-by":"crossref","unstructured":"Davids MS, Letai A. Targeting the B-cell lymphoma\/leukemia 2 family in cancer. J Clin Oncol. 2012; 30(25):3127-3135.","DOI":"10.1200\/JCO.2011.37.0981"},{"key":"56303","doi-asserted-by":"crossref","unstructured":"Valentin R, Grabow S, Davids MS. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018; 132(12):1248-1264.","DOI":"10.1182\/blood-2018-02-791350"},{"key":"56304","doi-asserted-by":"crossref","unstructured":"Souers AJ, Leverson JD, Boghaert ER. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-208.","DOI":"10.1038\/nm.3048"},{"key":"56305","doi-asserted-by":"crossref","unstructured":"Smith VM, Dietz A, Henz K. Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. Haematologica. 2020; 105(8):2150-2163.","DOI":"10.3324\/haematol.2019.220525"},{"key":"56306","doi-asserted-by":"crossref","unstructured":"Bojarczuk K, Wienand K, Ryan JA. Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019; 133(1):70-80.","DOI":"10.1182\/blood-2018-08-872465"},{"key":"56307","doi-asserted-by":"crossref","unstructured":"Davids MS, Roberts AW, Seymour JF. Phase I first-inhuman study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017; 35(8):826-833.","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"56308","doi-asserted-by":"crossref","unstructured":"Ryan JA, Brunelle JK, Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci U S A. 2010; 107(29):12895-12900.","DOI":"10.1073\/pnas.0914878107"},{"key":"56309","doi-asserted-by":"crossref","unstructured":"Tsao T, Shi Y, Kornblau S. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012; 91(12):1861-1870.","DOI":"10.1007\/s00277-012-1537-8"},{"key":"56310","doi-asserted-by":"crossref","unstructured":"Jin S, Cojocari D, Purkal JJ. 5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res. 2020; 26(13):3371-3383.","DOI":"10.1158\/1078-0432.CCR-19-1900"},{"key":"56311","doi-asserted-by":"crossref","unstructured":"Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-AZA-2\u2019-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res. 1984; 8(6):1043-1049.","DOI":"10.1016\/0145-2126(84)90059-6"},{"key":"56312","doi-asserted-by":"crossref","unstructured":"Gui\u00e8ze R, Liu VM, Rosebrock D. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019; 36(4):369-384.","DOI":"10.1016\/j.ccell.2019.08.005"},{"key":"56313","doi-asserted-by":"crossref","unstructured":"Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2\u2019-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics. 2013; 5(1):3.","DOI":"10.1186\/1868-7083-5-3"},{"key":"56314","doi-asserted-by":"crossref","unstructured":"Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008; 123(1):8-13.","DOI":"10.1002\/ijc.23607"},{"key":"56315","doi-asserted-by":"crossref","unstructured":"Gutierrez-Martinez P, Hogdal L, Nagai M. Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat Cell Biol. 2018; 20(4):413-421.","DOI":"10.1038\/s41556-018-0054-y"},{"key":"56316","doi-asserted-by":"crossref","unstructured":"Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378(6559):785-789.","DOI":"10.1038\/378785a0"},{"key":"56317","doi-asserted-by":"crossref","unstructured":"Bautista SJ, Boras I, Vissa A. mTOR complex 1 controls the nuclear localization and function of glycogen synthase kinase 3\u03b2. J Biol Chem. 2018; 293(38):14723-14739.","DOI":"10.1074\/jbc.RA118.002800"},{"key":"56318","doi-asserted-by":"crossref","unstructured":"Urakami S, Shiina H, Enokida H. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt\/\u03b2-catenin signaling pathway. Clin Cancer Res. 2006; 12(2):383-391.","DOI":"10.1158\/1078-0432.CCR-05-1344"},{"key":"56319","doi-asserted-by":"crossref","unstructured":"Jiang X, Wang Z, Ding B. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory\/relapsed acute myeloid leukemia patients. Oncotarget. 2015; 6(32):33612-33622.","DOI":"10.18632\/oncotarget.5600"},{"key":"56320","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Stevens BM, Jones CL. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018; 24(12):1859-1866.","DOI":"10.1038\/s41591-018-0233-1"},{"key":"56321","doi-asserted-by":"crossref","unstructured":"Bajpai R, Sharma A, Achreja A. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun. 2020; 11(1):1228.","DOI":"10.1038\/s41467-020-15051-z"},{"key":"56322","doi-asserted-by":"crossref","unstructured":"Stelling A, Wu CT, Bertram K. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma. Blood Adv. 2019; 3(20):3020-3032.","DOI":"10.1182\/bloodadvances.2019000210"},{"key":"56323","doi-asserted-by":"crossref","unstructured":"Chen ZX, Pervaiz S. Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells. Cell Death Differ. 2007; 14(9):1617-1627.","DOI":"10.1038\/sj.cdd.4402165"},{"key":"56324","doi-asserted-by":"crossref","unstructured":"Perciavalle RM, Stewart DP, Koss B. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012; 14(6):575-583.","DOI":"10.1038\/ncb2488"},{"key":"56325","doi-asserted-by":"crossref","unstructured":"Williams A, Hayashi T, Wolozny D. The non-apoptotic action of Bcl-xL: regulating Ca(2+) signaling and bioenergetics at the ER-mitochondrion interface. J Bioenerg Biomembr. 2016; 48(3):211-225.","DOI":"10.1007\/s10863-016-9664-x"},{"key":"56326","doi-asserted-by":"crossref","unstructured":"Escudero S, Zaganjor E, Lee S. Dynamic regulation of long-chain fatty acid oxidation by a noncanonical interaction between the MCL-1 BH3 helix and VLCAD. Mol Cell. 2018; 69(5):729-743.","DOI":"10.1016\/j.molcel.2018.02.005"},{"key":"56327","doi-asserted-by":"crossref","unstructured":"Roca-Portoles A, Rodriguez-Blanco G, Sumpton D. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death Dis. 2020; 11(8):1-13.","DOI":"10.1038\/s41419-020-02867-2"},{"key":"56328","doi-asserted-by":"crossref","unstructured":"Hotokezaka Y, Katayama I, Nakamura T. ATM-associated signalling triggers the unfolded protein response and cell death in response to stress. Commun Biol. 2020; 3(1):1-11.","DOI":"10.1038\/s42003-020-1102-2"},{"key":"56329","doi-asserted-by":"crossref","unstructured":"Chong SJF, Lai JXH, Qu J. A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression. Cancer Lett. 2019; 457:151-167.","DOI":"10.1016\/j.canlet.2019.05.009"},{"key":"56330","doi-asserted-by":"crossref","unstructured":"Chong SJF, Iskandar K, Lai JXH. Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020; 48(22):12727-12745.","DOI":"10.1093\/nar\/gkaa1110"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283245\/75916","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283245\/76439","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11189\/75916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:36Z","timestamp":1794045876000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283245","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,3]]}}}